- This 5-year partnership valued over SGD 32 million, is first-of-its-kind strategic partnership for Siemens Healthineers in the region.
- It focuses on upgrading HMI Group’s healthcare facilities, anchoring on digitalization and enhancing local talent pool.
- It includes further development of Centres of Excellence (CoEs) for Cancer, Neuroscience and Cardiovascular diseases, to improve treatment and patient care in these clinical areas.
SINGAPORE and JAKARTA, Indonesia, April 28, 2021 /PRNewswire/ — Health Management International (HMI Group) and Siemens Healthineers entered into a 5-year strategic partnership to advance healthcare delivery in Southeast Asia. As part of this first-of-its-kind partnership in the region, HMI Group will invest over SGD 32 million to roll out innovative medical technologies and digitalisation platforms, enhance clinical education and further develop Centres of Excellence (CoEs) in the key clinical areas of cancer, neuroscience and cardiovascular diseases. This investment is a key component of the HMI Group’s ongoing expansion initiatives across StarMed Specialist Centre in Singapore and tertiary hospitals in Malaysia — Mahkota Medical Centre (Mahkota) in Melaka and Regency Specialist Hospital (Regency) in Johor.
Singapore’s comprehensive ecosystem brings local and international players together to harness global trends of digital healthcare transformation and improving access to care. HMI Group’s prominence as a leading regional private healthcare services provider, coupled with Siemens Healthineers medtech expertise, together can contribute to a healthy society and healthcare ecosystem, enhancing Singapore’s position as a regional healthcare and digital hub.
Ms Chin Wei Jia, Group CEO of HMI Group, said, “This strategic partnership will enable HMI Group’s medical facilities to improve patient care by serving as flagship reference sites for Siemens Healthineers in Southeast Asia. As the care of our patients is at the center of everything that we do, our partnership will accelerate the adoption of connected health, thereby providing faster access to care, while building telehealth and predictive analytics capabilities at scale, all of which will go a long way in enhancing our patients’ journey towards a healthier outcome.”
According to Mr. Fabrice Leguet, Managing Director and Head of Siemens Healthineers, Southeast Asia, “At Siemens Healthineers, we understand the challenges that healthcare providers face in meeting the demand of providing quality healthcare. We are delighted to have signed this strategic partnership with HMI Group, which is first such for us in Southeast Asia. We will not only provide our innovative technology and digital solutions, but also support HMI Group to create value through enhanced training programs and provide healthcare consulting to further develop Centres of Excellence in the areas of cancer, neuroscience and cardiovascular. This will further position HMI Group as a leading quality healthcare provider in the region.”
As part of the pioneer cohort of Enterprise Singapore (ESG)’s Scale-up SG programme, HMI Group has made significant strides in digital transformation and community engagement to accelerate growth. Acquiring new capabilities through this partnership demonstrates HMI Group’s pursuit to unleash healthcare innovation to spur growth, develop higher value-added services and venture into new markets.
Mr. Ted Tan, Deputy Chief Executive Officer of Enterprise Singapore, said, “We would like to congratulate HMI Group and Siemens Healthineers on their strategic partnership. Building on the growth strategies developed through the Scale-up SG programme, we are confident that this partnership to leverage on digital technologies will further strengthen HMI as a leading healthcare provider in Southeast Asia.”
Tackling NCDs in Southeast Asia
About 62% of all deaths in Southeast Asia are due to non-communicable diseases (NCDs) like cancer, cardiovascular disorders (CVD) and diabetes[i]. According to WHO, about 74% of all deaths in Singapore, Malaysia and Indonesia are caused by NCDs[ii]. Early detection and tailored treatment using innovative technologies, while enhancing clinical knowledge, is becoming significantly important to address the rise in incidences of NCDs.
The further development of CoEs in the clinical areas of cancer, neuroscience and cardiovascular diseases, is part of HMI Group’s plans to deepen the use of digital health, big data and precision diagnosis, to transform how care is delivered and experienced. Especially now, given that countries are still recovering from the COVID-19 pandemic and the burden of NCDs on the ageing population. In 2035, the percentage of the population of Singapore above the age of 65 years was forecasted to reach 25.9%[iii].
Development of CoEs will require growing specialist talents within the region. Subsequently, HMI Group is looking at recruiting and developing local talents in the fields of clinical, allied health and hospital management, to meet the ever-evolving demand of patient care. Siemens Healthineers global consulting and clinical team, along with HMI Group will enhance the skills of this talent pool by training and knowledge transfer on the latest technologies and digital platforms.
Digitalization to enhance patient care
Singapore has always been in the forefront of embracing digital health solutions. Digital technologies will play an increasingly important role in addressing challenges like improving access and quality of care. Leveraging long-term partnerships supports in providing more holistic care in a patient’s journey with the adoption of digitalization. Artificial Intelligence (AI), remote monitoring, telehealth, are some of the current and future trends in the healthcare industry, which will be part of the CoE development at HMI Group.
Siemens Healthineers Biomatrix technology supported by AI in its MRI scanner, will allow scanning of every patient type by automatically adjusting to each individual patient, resulting in a higher diagnostic confidence, fewer rescans and more predictable scheduling. With its teamplay performance management applications and healthcare consulting services, HMI Group will be able to make quick and well-informed decisions to further improve the overall patient journey by eliminating bottlenecks like patient waiting times and quick reporting, among others.
Established earlier this calendar year, this partnership signals the start of a long-term relationship between Siemens Healthineers and HMI Group to advance healthcare delivery in the region. “The trend of providing consulting services to healthcare providers to build strong partnerships, exists in many parts of the world. We are happy that we are introducing this trend in Southeast Asia with HMI Group’s facilities, which will be Siemens Healthineers’ first reference site for Value Partnership in the region. Developing HMI Group’s facilities as a reference site will demonstrate how Value Partnerships play a critical role to overcome the increasing challenges in the industry today,” adds Leguet.
This collaboration with HMI Group is a long-term Value Partnership. This partnership model with Siemens Healthineers enables healthcare providers to optimize business processes, expand capabilities, and advance innovation. It spans on the entire Siemens Healthineers portfolio, to generate added value above and beyond equipment itself. Value Partnerships are designed to fit the customer’s needs entirely. Siemens Healthineers has formed Value Partnerships with many healthcare providers around the world. The latest examples include Hamilton Health Sciences in Canada, the University of Missouri System in the USA, Dallah Health Company in Saudi Arabia and Braunschweig Municipal Hospital in Germany.
“HMI Group is committed to not just improve the lives of our patients by providing access to better solutions, but the community as a whole by supporting local talents and through continual investment in medical technologies, ultimately raising the bar for care delivery of the future. Our partnership with Siemens Healthineers, will contribute towards our achievement of this goal,” said Chin.
[i] WHO Noncommunicable diseases in the South-East Asia: https://www.who.int/southeastasia/health-topics/noncommunicable-diseases
[iii] Statista 2021
The product names and/or brands referred to are the property of their respective trademark holders.
The products, services and/or features mentioned here are not commercially available in all countries and/or for all modalities. Their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
This press release and a press picture is available here
About HMI Group
Founded in 1998, Health Management International Pte. Ltd. (“HMI Group”) is a growing regional private healthcare provider with presence in Singapore, Malaysia, and Indonesia. HMI Group operates two tertiary hospitals in Malaysia, Mahkota Medical Centre and Regency Specialist Hospital. In Singapore, the Group operates StarMed Specialist Centre, a one-stop ambulatory care centre and owns a stake in OneCare Medical Group, a chain of GP clinics. The Group’s training arm, HMI Institute of Health Sciences, is a social enterprise which trains numerous graduates for the Singapore healthcare sector. The Group also operates a network of patient representative offices in Indonesia, Malaysia, and Singapore. HMI Group is focused on growing its existing healthcare businesses, as well as expanding its presence regionally. HMI Group places great emphasis on medical, operational, and service excellence, as well as continual investment in technology and its people. HMI Group’s vision is to be a leading healthcare group in Asia. HMI Group’s dedicated team of doctors, nurses, and healthcare staff, supported by experienced hospital management, enables HMI Group to attend to close to 1 million patients annually. HMI Group is committed to deliver comprehensive, quality, and value-based healthcare services to become a trusted healthcare provider in Asia. Further information is available at www.hmi.com.sg
About Siemens Healthineers
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of EUR14.5 billion and adjusted EBIT of EUR2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 65,000 employees worldwide. Further information is available at www.siemens-healthineers.com/en-sg
SOURCE Siemens Healthineers